Movement Alert｜Veeva Intraday Rise 3.59% in Regular Trading, IQVIA Expands Partnership to Use Its Clinical Development Applications

Market Focus10-15

On October 15, Veeva rose 3.59% in Regular Trading, trading near $308.31 per share, with turnover of $149 million.

The move coincided with IQVIA announcing it selected four Veeva enterprise standard applications for use across its clinical development studies: Clinical Trial Management System, eTMF, Study Startup, and Site Connect.

The expanded partnership is intended to improve clinical trial efficiency and coordination. No financial terms were disclosed, but the announcement reinforces Veeva’s position in life sciences R&D cloud software. Recent backdrop has also been constructive: Veeva reported fiscal second-quarter revenue of $928.0 million and adjusted EPS of $2.35 in late August, both above consensus, and raised full-year guidance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment